MedTrace Logo

The Effect of Imipramine on Early Information Processing

NCT00206999 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2011-09-20

No results posted yet for this study

Summary

We wanted to compare the relation of two different psychophysiological paradigms (PrePulse Inhibition of the startle response = PPI and P50 suppression) to each other. Additionally, we wanted to test the effect of the combined serotonin- and noradrenaline re-uptake inhibitor, imipramine, on these measures. The primary hypothesis was that PPI and P50 gating would not correlate with each other at baseline. The secondary hypothesis was that increased noradrenergic and serotonergic activity would disrupt PPI as well as P50 gating.

Conditions

  • Healthy Volunteers

Interventions

DRUG

imipramine

Either 50 mg of imipramine or placebo will be administered to healthy male volunteers

Sponsors & Collaborators

  • University of Copenhagen

    collaborator OTHER

  • Glostrup University Hospital, Copenhagen

    collaborator OTHER

  • The Danish Medical Research Council

    collaborator OTHER

  • Lundbeck Foundation

    collaborator OTHER

  • Birte Glenthoj

    lead OTHER

Principal Investigators

  • Birte Glenthoj, MD, DMSc. · Center for Neuropsychiatric Schizophrenia Research, University of Copenhagen, Psychaitric Center Glostrup, Ndr. Ringvej, DK-2600 Glostrup, Denmark

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-09-30
Primary Completion
2006-01-31
Completion
2006-01-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00206999 on ClinicalTrials.gov